Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 18/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.57 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698408 | 0.92 | OPRM1 (0.74) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL5755550 | 0.85 | OPRM1 (0.78) | OPRM1KCNH2OPRD1OPRK1NR3C1 | |
| SCHEMBL5754361 | 0.84 | OPRM1 (0.64) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL4702137 | 0.83 | OPRM1 (0.60) | OPRM1KCNH2OPRD1OPRK1NR3C1 | |
| SCHEMBL4754480 | 0.81 | OPRM1 (0.86) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL5755436 | 0.80 | OPRM1 (0.78) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL7070109 | 0.80 | KCNH2 (0.60) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL4701734 | 0.79 | KMT2A (0.41) | OPRM1 | |
| SCHEMBL4700198 | 0.79 | OPRM1 (0.63) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL5755072 | 0.79 | OPRM1 (0.66) | OPRM1KCNH2OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1440059-B1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070054950-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | PFIZER INC. | 2007-03-08 | — | — | US | disclosed |
| US-7049335-B2 | 3-azabicyclo[3.1.0]hexane derivatives | PFIZER INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20050171178-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| US-20030087898-A1 | 3-azabicyclo[3.1.0]hexane derivatives | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087898-A1 | 3-azabicyclo[3.1.0]hexane derivatives | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885KCNH2 542/4885OPRD1 1/4885 |
| US-20050171178-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885KCNH2 561/4885OPRD1 1/4885 |
| US-20070054950-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885KCNH2 546/4885OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.